Establishment Labs (NASDAQ:ESTA) Releases Earnings Results, Beats Estimates By $0.13 EPS

Establishment Labs (NASDAQ:ESTA) announced its quarterly earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13, FiscalAI reports. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. The firm had revenue of $64.62 million for the quarter, compared to analyst estimates of $63.80 million. During the same period last year, the business earned ($1.19) EPS. Establishment Labs’s revenue for the quarter was up 45.2% compared to the same quarter last year.

Here are the key takeaways from Establishment Labs’ conference call:

• Strong financial momentum — Q4 revenue was $64.6M (+45.2% y/y) and 2025 revenue was $211.1M (+27.2%), with Q4 adjusted EBITDA of +$5.5M versus -$13.1M a year ago and guidance of $264M–$266M for 2026 while expecting quarterly adjusted EBITDA positivity and full-year cash-flow positivity in 2027.
• Rapid U.S. adoption of Motiva — U.S. Motiva revenue was $45.6M in 2025, the company reports ~20% augmentation market share exiting 2025, 1,500+ U.S. accounts onboarded, and plans to add up to 15 more sales reps to accelerate share gains.
• Preserve minimally invasive platform is expanding the market — Early data show Preserve draws new patients (≈15% were not previously considering augmentation), commands ~2x pricing versus traditional augmentation, and is expected to contribute to >$30M in global demand in 2026 with 200 surgeons targeted for training in 2026.
• Pipeline and international expansion — OUS direct markets grew strongly (Europe direct >20%), China performance is improving but requires distributor work, and Motiva reconstruction was submitted to the FDA (recon could materially expand U.S. TAM and ASPs but is expected to drive revenue mainly in 2027+).
• Corporate and capital position — Management is transitioning (new CFO Cassandra Harris; Raj to SVP, Global Strategy), cash was $75.6M at year-end with no planned equity raises, and the company is evaluating refinancing options as its credit facility enters its final year.

Establishment Labs Stock Up 6.3%

ESTA opened at $79.67 on Wednesday. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $79.90. The business has a 50 day moving average price of $70.99 and a two-hundred day moving average price of $57.73. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06. The company has a market cap of $2.32 billion, a PE ratio of -28.05 and a beta of 0.99.

Key Establishment Labs News

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q4 beat on both EPS and revenue: EST A reported ($0.09) EPS vs. consensus ($0.22) and revenue of $64.62M (up 45% YoY), signaling accelerating sales recovery and margin improvement potential. Read More.
• Positive Sentiment: 2026 revenue guidance and growth target: management guided FY-2026 revenue of $264–266M and is targeting at least 25% revenue growth while expanding minimally invasive platforms — a clear revenue-growth thesis for investors. Read More.
• Positive Sentiment: Analyst optimism: Needham raised its price target to $86 and kept a Buy rating, providing third-party validation and incremental buy-side support. Read More.
• Neutral Sentiment: Leadership transition announced to support next growth phase — could be constructive but depends on execution and message from new leadership. Read More.
• Neutral Sentiment: Full Q4/2025 disclosure and call details are available (earnings call transcript published), useful for assessing management commentary on margin levers and commercialization cadence. Read More.
• Neutral Sentiment: Industry/peer coverage and previews note narrowing losses and improving trends but don’t change the profitability timeline. Read More.
• Negative Sentiment: Company remains unprofitable with a negative net margin (~-43%) and negative ROE; sell-side still models negative EPS for the year — execution risks and profitability timeline could cap upside. Read More.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Quarry LP acquired a new stake in shares of Establishment Labs during the third quarter worth $34,000. Kestra Advisory Services LLC acquired a new position in Establishment Labs in the 4th quarter valued at $47,000. Osaic Holdings Inc. raised its position in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the last quarter. PharVision Advisers LLC purchased a new position in Establishment Labs during the 3rd quarter worth $203,000. Finally, Twinbeech Capital LP acquired a new stake in shares of Establishment Labs in the 4th quarter worth $214,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. JPMorgan Chase & Co. lifted their target price on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Citigroup raised their price target on Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Mizuho boosted their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Finally, Canaccord Genuity Group raised their target price on shares of Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Establishment Labs currently has an average rating of “Moderate Buy” and an average target price of $79.14.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.